Page 10 - Graphite Bio News Today

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 4,030,000 shares, a growth of 33.0% from the March 15th total of 3,030,000 shares. Based on an average daily volume of 296,200 shares, the […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) insider Phil Gutry purchased 5,000 shares of the stock in a transaction that occurred on Monday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $20,050.00. Following the completion of the acquisition, the insider now owns 299,941 shares […]

Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) major shareholder Biocapital L.P. Samsara acquired 74,464 shares of the firm’s stock in a transaction that occurred on Monday, April 11th. The stock was acquired at an average price of $4.07 per share, with a total value of $303,068.48. Following the completion of the acquisition, the insider now […]

Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have been given an average rating of “Buy” by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 […]

We have used the March return data of small-cap stocks to rank the ten worst performing small-cap stocks in March 2022.

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Graphite Bio, Inc. ("Graphite" or the "Company") (NASDAQ: GRPH). Such investors...

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Graphite Bio, Inc. ("Graphite" or the "Company") (NASDAQ: GRPH). Such investors...

Graphite Bio (NASDAQ:GRPH – Get Rating) had its price objective dropped by stock analysts at SVB Leerink from $34.00 to $18.00 in a note issued to investors on Tuesday, MarketBeat.com reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s target price would suggest a potential upside of 219.72% from the stock’s […]

BioPharma

Press release content from Globe Newswire. The AP news staff was not involved in its creation.